GGrantIndex
← Leaderboards

Zhe Li

Brigham And Women'S Hospital

$8,930,965
Attributed
$8,930,965
Total exposure
11
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $963.1K · FY200725
$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,930,965 · 11

By mechanism

R01$6,081,548 · 4
R21$1,244,872 · 3
R00$735,086 · 1
UH3$445,499 · 1
K99$273,960 · 1
UH2$150,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsCellsMutationMouse ModelBaseMolecularCell TypeGenesAffectIn VivoPathway InteractionsMalignant Breast NeoplasmCancer TypeEpigenetic ProcessOncogenicEventStem CellsLeadBreast Epithelial CellsEpithelial CellsNeoplastic CellSelf-RenewalCancer InitiationCancer Cell

Grant awards (32)

DNA damage-related stemness program during BRCA1 breast cancer initiation$527,159
R01 · FY2025 · CA · contact PI
Mechanism of LSD1 in breast cancer metastasis suppression$380,549
R01 · FY2025 · CA · contact PI
Mechanism of LSD1 in breast cancer metastasis suppression$361,522
R01 · FY2024 · CA · contact PI
Mechanism of LSD1 in breast cancer metastasis suppression$372,938
R01 · FY2023 · CA · contact PI
Mechanism of LSD1 in breast cancer metastasis suppression$372,938
R01 · FY2022 · CA · contact PI
Interplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant field$367,270
R01 · FY2022 · CA · contact PI
Development of a clinically relevant mouse model of ER+ breast cancer$222,862
R21 · FY2022 · CA · contact PI
Mechanism of LSD1 in breast cancer metastasis suppression$380,549
R01 · FY2021 · CA · contact PI
Interplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant field$374,766
R01 · FY2021 · CA · contact PI
Development of a clinically relevant mouse model of ER+ breast cancer$191,479
R21 · FY2021 · CA · contact PI
Interplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant field$374,766
R01 · FY2020 · CA · contact PI
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion$150,000
UH3 · FY2020 · CA · contact PI
Interplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant field$363,522
R01 · FY2019 · CA · contact PI
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion$145,499
UH3 · FY2019 · CA · contact PI
Interplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant field$374,766
R01 · FY2018 · CA · contact PI
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion$150,000
UH3 · FY2018 · CA · contact PI
CRISPR/Cas9-based lineage tracing for fate mapping of cancer cells and stem cells$207,365
R21 · FY2017 · CA · contact PI
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion$90,000
UH2 · FY2017 · CA · contact PI
CRISPR/Cas9-based lineage tracing for fate mapping of cancer cells and stem cells$212,575
R21 · FY2016 · CA · contact PI
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion$60,000
UH2 · FY2016 · CA · contact PI
IGF/IGF1R signaling in hematopoiesis and leukemogenesis$363,125
R01 · FY2015 · HL · contact PI
Lineage tracing and clonal analysis of oral cancer initiating cells$219,018
R21 · FY2015 · DE · contact PI
IGF/IGF1R signaling in hematopoiesis and leukemogenesis$361,282
R01 · FY2014 · HL · contact PI
Lineage tracing and clonal analysis of oral cancer initiating cells$191,573
R21 · FY2014 · DE · contact PI
IGF/IGF1R signaling in hematopoiesis and leukemogenesis$355,443
R01 · FY2013 · HL · contact PI
IGF/IGF1R signaling in hematopoiesis and leukemogenesis$373,365
R01 · FY2012 · HL · contact PI
IGF/IGF1R signaling in hematopoiesis and leukemogenesis$377,588
R01 · FY2011 · HL · contact PI
Breast cancer stem cells and their cellular origin$238,599
R00 · FY2011 · CA · contact PI
Breast cancer stem cells and their cellular origin$247,487
R00 · FY2010 · CA · contact PI
Breast cancer stem cells and their cellular origin$249,000
R00 · FY2009 · CA · contact PI
Breast cancer stem cells and their cellular origin$136,820
K99 · FY2008 · CA · contact PI
Breast cancer stem cells and their cellular origin$137,140
K99 · FY2007 · CA · contact PI